EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells

An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Oncol
Egile Nagusiak: Chiu, Huan-Chih, Chang, Teng-Yuan, Huang, Chin-Ting, Chao, Yu-Sheng, Hsu, John T.-A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2012
Gaiak:
Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/
https://ncbi.nlm.nih.gov/pubmed/22366308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak